Switch theme
Sign up to access all valuation multiples
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
2015
188
LTM Revenue $49.0M
LTM EBITDA -$274M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kymera Therapeutics has a last 12-month revenue of $49.0M and a last 12-month EBITDA of -$274M.
In the most recent fiscal year, Kymera Therapeutics achieved revenue of $47.1M and an EBITDA of -$216M.
Kymera Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kymera Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $78.6M | $47.1M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$143M | -$216M | XXX | XXX | XXX |
| EBITDA Margin | -182% | -459% | XXX | XXX | XXX |
| Net Profit | -$155M | -$147M | XXX | XXX | XXX |
| Net Margin | -197% | -312% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Kymera Therapeutics's stock price is $25.
Kymera Therapeutics has current market cap of $1.7B, and EV of $1.3B.
See Kymera Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.7B | XXX | XXX | XXX | XXX | $-3.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Kymera Therapeutics has market cap of $1.7B and EV of $1.3B.
Kymera Therapeutics's trades at 25.5x LTM EV/Revenue multiple, and -4.6x LTM EBITDA.
Analysts estimate Kymera Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Kymera Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 26.6x | XXX | XXX | XXX |
| EV/EBITDA | -5.8x | XXX | XXX | XXX |
| P/E | -7.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -6.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpKymera Therapeutics's NTM/LTM revenue growth is 18%
Kymera Therapeutics's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $1.6M for the same period.
Over next 12 months, Kymera Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Kymera Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Kymera Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -40% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -459% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 51% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -442% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 135% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 510% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 645% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kymera Therapeutics acquired XXX companies to date.
Last acquisition by Kymera Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Kymera Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Kymera Therapeutics founded? | Kymera Therapeutics was founded in 2015. |
| Where is Kymera Therapeutics headquartered? | Kymera Therapeutics is headquartered in United States of America. |
| How many employees does Kymera Therapeutics have? | As of today, Kymera Therapeutics has 188 employees. |
| Who is the CEO of Kymera Therapeutics? | Kymera Therapeutics's CEO is Dr. Nello Mainolfi, PhD. |
| Is Kymera Therapeutics publicy listed? | Yes, Kymera Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Kymera Therapeutics? | Kymera Therapeutics trades under KYMR ticker. |
| When did Kymera Therapeutics go public? | Kymera Therapeutics went public in 2020. |
| Who are competitors of Kymera Therapeutics? | Similar companies to Kymera Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kymera Therapeutics? | Kymera Therapeutics's current market cap is $1.7B |
| What is the current revenue of Kymera Therapeutics? | Kymera Therapeutics's last 12-month revenue is $49.0M. |
| What is the current EBITDA of Kymera Therapeutics? | Kymera Therapeutics's last 12-month EBITDA is -$274M. |
| What is the current EV/Revenue multiple of Kymera Therapeutics? | Current revenue multiple of Kymera Therapeutics is 25.5x. |
| What is the current EV/EBITDA multiple of Kymera Therapeutics? | Current EBITDA multiple of Kymera Therapeutics is -4.6x. |
| What is the current revenue growth of Kymera Therapeutics? | Kymera Therapeutics revenue growth between 2023 and 2024 was -40%. |
| Is Kymera Therapeutics profitable? | Yes, Kymera Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
